Chennai, Aug 04: Dr. Agarwal’s Health Care Limited opened FY27 with its strongest quarter on record. Revenue from operations grew 26.0% year-on-year to ₹614 crore, EBITDA rose 25.2% to ₹177 crore with margins resilient at 28.5%, and profit after tax surged 44.6% to ₹55 crore — profit growth outpacing revenue growth even as the Company absorbed higher greenfield investments.
Performance was anchored by the Company’s mature facilities, which grew revenue 16.3% year-on-year, alongside 91,082 surgeries performed during the quarter, up 15.5%. The Company commissioned 18 greenfield facilities — 1 tertiary, 15 secondary and 2 primary — including 16 surgical facilities, its highest-ever addition in a single quarter, taking the network to 304 eye care facilities across 10 countries. It plans to add another 42 facilities through the remainder of FY27, deepening its footprint across both established and emerging markets.
The Company’s growth strategy rests on two engines: sustained growth across mature centres, and accelerated greenfield expansion into under-served markets.
Commenting on the performance for Q1 FY2027, Dr. Adil Agarwal, CEO, Dr. Agarwal’s Health Care Limited, said: “What makes this quarter significant isn’t just the growth — we delivered our highest-ever sequential revenue growth while simultaneously commissioning more surgical facilities than in any quarter in our history. At the heart of this momentum is something no metric captures — the deepening trust patients place in us, bringing us their own and their families’ eye care. Mature centres funding aggressive expansion is exactly our model working as designed. With 42 more facilities planned this year, we are building density in markets where quality eye care remains out of reach for many in need. Backed by strong execution capabilities and a healthy expansion pipeline, we remain firmly on track to achieve our growth objectives for the year.”